《柳叶刀Gastroenterol Hepatol 2023》修正；8: 976 - 89

IF 38.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Lancet Gastroenterology & Hepatology Pub Date : 2025-02-12 DOI:10.1016/s2468-1253(25)00003-2

{"title":"《柳叶刀Gastroenterol Hepatol 2023》修正；8: 976 - 89","authors":"","doi":"10.1016/s2468-1253(25)00003-2","DOIUrl":null,"url":null,"abstract":"Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol 2023; 8: 976–89—In this Article, the declaration of interest statement for PDRH should read: “PDRH has received grants from AbbVie, the Crohn's & Colitis Foundation, the National Institutes of Health, and Takeda; and has served as a consultant for AbbVie, Eli Lilly, the Gastrointestinal Health Foundation, Imedex, Pfizer, Takeda, and Vindico Medical Education.” This correction has been made to the online version as of Feb 12, 2025.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"15 1","pages":""},"PeriodicalIF":38.6000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89\",\"authors\":\"\",\"doi\":\"10.1016/s2468-1253(25)00003-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol 2023; 8: 976–89—In this Article, the declaration of interest statement for PDRH should read: “PDRH has received grants from AbbVie, the Crohn's & Colitis Foundation, the National Institutes of Health, and Takeda; and has served as a consultant for AbbVie, Eli Lilly, the Gastrointestinal Health Foundation, Imedex, Pfizer, Takeda, and Vindico Medical Education.” This correction has been made to the online version as of Feb 12, 2025.\",\"PeriodicalId\":56028,\"journal\":{\"name\":\"Lancet Gastroenterology & Hepatology\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":38.6000,\"publicationDate\":\"2025-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Gastroenterology & Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2468-1253(25)00003-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(25)00003-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Vermeire S, Danese S，周伟，等。upadacitinib维持治疗对8周诱导治疗（U-ACHIEVE维持）有反应的中度至重度活动性溃疡性结肠炎患者的疗效和安全性：来自随机、安慰剂对照、双盲、3期维持研究的总体结果。Lancet Gastroenterol Hepatol 2023；[08:976 - 89]在这篇文章中，PDRH的利益声明应该这样写：“PDRH获得了艾伯维、克罗恩病和安培公司的资助。结肠炎基金会、美国国立卫生研究院和武田；并曾担任艾伯维、礼来、胃肠健康基金会、Imedex、辉瑞、武田和Vindico医学教育的顾问。”此更正已于2025年2月12日对在线版本进行了修改。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89

Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol 2023; 8: 976–89—In this Article, the declaration of interest statement for PDRH should read: “PDRH has received grants from AbbVie, the Crohn's & Colitis Foundation, the National Institutes of Health, and Takeda; and has served as a consultant for AbbVie, Eli Lilly, the Gastrointestinal Health Foundation, Imedex, Pfizer, Takeda, and Vindico Medical Education.” This correction has been made to the online version as of Feb 12, 2025.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Gastroenterology & Hepatology Medicine-Hepatology

CiteScore

50.30

自引率

1.10%

发文量

期刊介绍： The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.